MARKET

PBYI

PBYI

Puma Biotec
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.48
-0.38
-3.50%
After Hours: 10.48 0 0.00% 17:22 03/08 EST
OPEN
10.86
PREV CLOSE
10.86
HIGH
10.93
LOW
10.42
VOLUME
295.43K
TURNOVER
--
52 WEEK HIGH
14.14
52 WEEK LOW
5.50
MARKET CAP
421.91M
P/E (TTM)
-6.9193
1D
5D
1M
3M
1Y
5Y
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology reported the grant of an inducement award approved by the BOD on March 4, 2021, as required by Nasdaq Listing Rule 5635(c)(4).
Business Wire · 4h ago
Breast Cancer Therapeutics Market Size, Share & Trends Analysis Report With Growth Forecast 2020-2027
Mar 08, 2021 (Heraldkeepers) -- Global breast cancer therapeutics market share consists of several players including Teva Pharmaceutical Industries, Puma...
Heraldkeepers · 9h ago
EQS-Adhoc: Polyphor announces financial results for the full-year 2020
EQS Group-Ad-hoc: Polyphor AG / Key word(s): Annual Results Polyphor announces financial results for the full-year 2020 05-March-2021 / 07:15 CET/CEST...
EQS Group AG · 3d ago
Polyphor Announces Financial Results for the Full-Year 2020
Phase III trial patient enrollment for balixafortide completed in Q4 2020 despite COVID-19. Results expected for ORR and PFS in Q2 and Q4 2021 respectivelyExclusive licensing agreement for balixafortide in China with Fosun PharmaClinical Trial Authorizatio...
GlobeNewswire · 3d ago
Puma Biotechnology to Present at the Barclays Global Healthcare Conference
Alan Auerbach, CEO & President, will present an overview of Puma Biotechnology at the virtual Barclays Global Healthcare Conference on March 11, 2021.
Business Wire · 4d ago
Puma Biotechnology (PBYI) Receives a Sell from J.P. Morgan
SmarterAnalyst · 4d ago
Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright Global Life Sciences Con...
BusinessWire · 6d ago
Puma Biotechnology (PBYI) Receives a Hold from Leerink Partners
In a report issued on February 26, Andrew Berens from Leerink Partners maintained a Hold rating on Puma Biotechnology (PBYI), with a price target of
SmarterAnalyst · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PBYI. Analyze the recent business situations of Puma Biotec through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PBYI stock price target is 10.33 with a high estimate of 16.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 240
Institutional Holdings: 41.54M
% Owned: 103.19%
Shares Outstanding: 40.26M
TypeInstitutionsShares
Increased
38
2.60M
New
35
-593.68K
Decreased
41
2.81M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Chief Executive Officer/President/Director
Alan Auerbach
Chief Financial Officer
Maximo Nougues
Senior Vice President
Douglas Hunt
Chief Scientific Officer
Richard Bryce
Lead Director/Independent Director
Jay Moyes
Director
Brian Stuglik
Independent Director
Ann Miller
Independent Director
Michael Miller
Independent Director
Hugh O Dowd
Independent Director
Adrian Senderowicz
Independent Director
Troy Wilson
No Data
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib, oral), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Webull offers kinds of Puma Biotechnology Inc stock information, including NASDAQ:PBYI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBYI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PBYI stock methods without spending real money on the virtual paper trading platform.